Despite a significant decline in deaths in children younger than 5 years globally in the past
three decades, preventable and treatable infectious diseases remain the leading cause of …

Neonatal sepsis causes up to an estimated 680,000 deaths annually worldwide,
predominantly in low-and middle-income countries (LMICs). A significant and growing …

Neonatal Infections are among the most common reasons for admission to the intensive
care unit. Neonatal sepsis (NS) significantly contributes to mortality rates. Empiric antibiotic …

The current demand for pharmacometricians outmatches the supply provided by academic
institutions and considerable investments are made to develop the competencies of these …

Background Pharmacokinetic (PK) data underlying paediatric penicillin dosing remain
limited, especially in critical care. Objectives The primary objective of the Neonatal and …

Background Neonatal sepsis is a serious bacterial infection of neonates, globally killing up
to 680 000 babies annually. It is frequently complicated by antimicrobial resistance …

The aim of this study was to investigate the pharmacokinetics of multiple-dose intravenous
(iv) fosfomycin in critically ill patients during continuous venovenous hemodialysis (CVVHD) …

Antimicrobial resistance has become a significant public health problem globally with
multidrug resistant Gram negative (MDR-GN) bacteria being the main representatives. The …

Objective To assess pharmacokinetics and changes to sodium levels in addition to adverse
events (AEs) associated with fosfomycin among neonates with clinical sepsis. Design A …

Antimicrobial resistance increasingly complicates neonatal sepsis in a global context.
Fosfomycin and amikacin are two agents being tested in an ongoing multicenter neonatal …